Conexeu Sciences INC

Conexeu Sciences Inc. disclosed the issuance of over 1.4 million unregistered shares and warrants between June and September 2026, primarily for working capital and consulting services.

Conexeu Sciences announced the completion of its 12-month P.R.O.O.F preclinical study for its CXU platform, demonstrating tissue restoration and injectable performance, paving the way for a planned 510(k) submission in wound care by Q1 2027.

David Robert Bogart, Chief Commercial Officer and a Director of Conexeu Sciences Inc., reported multiple transactions in common stock on September 25, 2026.

Jeffrey Nathan Sharpe, a Director of Conexeu Sciences Inc., reported multiple transactions in common stock on September 14, 2026.

Lynn Sebastian Purcell, a Director and 10% owner of Conexeu Sciences Inc., reported multiple transactions in common stock on September 4, 2026.

Lynn Sebastian Purcell, a Director and 10% owner of Conexeu Sciences Inc., reported multiple transactions in common stock on September 4, 2026.

Jeffrey Sharpe increased his beneficial ownership of Conexeu Sciences Inc. common stock to 5.2% following the exercise of performance warrants tied to a market capitalization milestone.

Jeffrey Sharpe has increased his beneficial ownership in Conexeu Sciences Inc. to 5.4% following the vesting of performance warrants tied to market capitalization milestones.

Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund has reported beneficial ownership of 4,314,336 shares, representing 9.99% of Conexeu Sciences Inc.'s common stock, including exercisable warrants.

Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund has reported beneficial ownership of 4,400,305 shares, representing 9.99% of Conexeu Sciences Inc.'s common stock, including warrants with exercise limitations.

David Bogart has filed a Schedule 13G, reporting beneficial ownership of 2,293,750 shares, representing 8.1% of Conexeu Sciences Inc.'s common stock.

Michael G. Wright has reported beneficial ownership of 12.1% of Conexeu Sciences Inc. common stock as of June 30, 2026.

Paisley Capital Holdings Corp. has reported beneficial ownership of 1,800,000 shares, representing 6.7% of the common stock of Conexeu Sciences Inc.